Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su nuovi agenti antitumorali in pazienti con carcinoma mammario triplo negativo metastatico (BEGONIA)

9 novembre 2026 aggiornato da: AstraZeneca

Uno studio di fase IB/II, in 2 fasi, in aperto, multicentrico per determinare l'efficacia e la sicurezza di Durvalumab (MEDI4736) + Paclitaxel e Durvalumab (MEDI4736) in combinazione con nuove terapie oncologiche con o senza paclitaxel per la tripla metastatica di prima linea Cancro al seno negativo

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Panoramica dello studio

Descrizione dettagliata

This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.

Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 may expand patient enrollment if adequate efficacy signal is observed in Part 1. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

243

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • Research Site
    • Ontario
      • London, Ontario, Canada, N6A 4L6
        • Research Site
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Research Site
      • Montreal, Quebec, Canada, H4A 3J1
        • Research Site
      • Seoul, Corea del Sud, 03080
        • Research Site
      • Seoul, Corea del Sud, 05505
        • Research Site
      • Seoul, Corea del Sud, 06351
        • Research Site
      • Gdansk, Polonia, 80-952
        • Research Site
      • Krakow, Polonia, 31-501
        • Research Site
      • Lublin, Polonia, 20-090
        • Research Site
      • Opole, Polonia, 45-060
        • Research Site
      • Rzeszów, Polonia, 35-021
        • Research Site
      • Warsaw, Polonia, 02-781
        • Research Site
      • Warsaw, Polonia, 04-141
        • Research Site
      • Cambridge, Regno Unito, CB2 0QQ
        • Research Site
      • London, Regno Unito, EC1M 6BQ
        • Research Site
      • Manchester, Regno Unito, M20 4BX
        • Research Site
      • Oxford, Regno Unito, OX3 7LE
        • Research Site
    • Arizona
      • Tucson, Arizona, Stati Uniti, 85715
        • Research Site
    • Maryland
      • Columbia, Maryland, Stati Uniti, 21044
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Research Site
      • Boston, Massachusetts, Stati Uniti, 02215
        • Research Site
    • Michigan
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Research Site
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Research Site
    • Texas
      • Dallas, Texas, Stati Uniti, 75246
        • Research Site
    • Virginia
      • Williamsburg, Virginia, Stati Uniti, 23188
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Research Site
      • Taichung, Taiwan, 40447
        • Research Site
      • Tainan, Taiwan, 70403
        • Research Site
      • Taipei, Taiwan, 10002
        • Research Site
      • Taipei, Taiwan, 112
        • Research Site
      • Taoyuan, Taiwan, 333
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 130 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion criteria

  1. Female
  2. At least 18 years of age at the time of screening
  3. Patient must have locally confirmed advanced/unresectable or metastatic TNBC.
  4. No prior treatment for metastatic (Stage IV) TNBC
  5. Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
  6. WHO/ECOG status at 0 or 1 at enrollment

Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)

Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have PD-L1 positive tumor as determined by an IHC based assay

Exclusion criteria

  1. History of allogeneic organ transplantation
  2. Active or prior documented autoimmune or inflammatory disorders
  3. Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies)
  4. Untreated CNS metastases
  5. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
  6. Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
  7. Female patients who are pregnant, breastfeeding
  8. Cardiac Ejection Fraction less than 50%

Patients enrolled in Arm 2 only:

  1. Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
  2. Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
  3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
  4. Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.

Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months

Patients enrolled in Arm 7 and 8 only: Clinically significant corneal disease in the opinion of the Investigator.

Patients enrolled in Arm 6, 7 and 8 only:

  1. History of or active interstitial lung disease/pneumonitis
  2. Use of chloroquine or hydroxychloroquine in <14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
  3. Patients enrolled in Arm 6 only: Previously been diagnosed as HER2+ or received HER2-targeted therapy.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1

durvalumab + paclitaxel

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Altri nomi:
  • MEDI4736

Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Sperimentale: Arm 2

durvalumab + paclitaxel + capivasertib

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Altri nomi:
  • MEDI4736

Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off

Altri nomi:
  • AZD5363
Sperimentale: Arm 5

durvalumab + paclitaxel + oleclumab

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Altri nomi:
  • MEDI4736

Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1

Altri nomi:
  • MEDI9447
Sperimentale: Arm 6

durvalumab + trastuzumab deruxtecan

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Altri nomi:
  • MEDI4736

Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w

Altri nomi:
  • DS-8201a
Sperimentale: Arm 7

durvalumab + datopotamab deruxtecan

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Altri nomi:
  • MEDI4736

Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Altri nomi:
  • Dato-DXd; DS-1062a
Sperimentale: Arm 8

durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status)

Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Altri nomi:
  • MEDI4736

Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Altri nomi:
  • Dato-DXd; DS-1062a

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Dose Limiting Toxicity (DLT) Events
Lasso di tempo: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))

The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients

From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response Rate (ORR)
Lasso di tempo: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR.

Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Progression-free Survival (PFS)
Lasso di tempo: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)

Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Duration of Response (DoR)
Lasso di tempo: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)

Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date

Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
Overall Survival (Count)
Lasso di tempo: From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)

Number of patients with overall survival, the time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause

From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Overall Survival (Duration)
Lasso di tempo: From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)

Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause

From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
Progression-free Survival at 6 Months (PFS6)
Lasso di tempo: 6 months following date of first dose

Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy])

6 months following date of first dose

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Peter Schmid, MD, PhD, Barts Cancer Institute

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

21 dicembre 2018

Completamento primario (Effettivo)

29 novembre 2024

Completamento dello studio (Stimato)

26 febbraio 2027

Date di iscrizione allo studio

Primo inviato

25 ottobre 2018

Primo inviato che soddisfa i criteri di controllo qualità

14 novembre 2018

Primo Inserito (Effettivo)

15 novembre 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi